Shire plc, maker of the ADHD medication Vyvanse, has acquired the worldwide rights to a medication called Equasym - which is also used for the treatment of ADHD.

"This acquisition will broaden the scope of Shire's ADHD portfolio and will facilitate immediate access to the European ADHD market as well as provide Shire the opportunity to enter additional world markets."

The agreement between Shire and Equasym maker UCB was announced yesterday. Shire will reportedly pay UCB about $70 million in exchange for the acquisition. Source: PR Newswire

Labels: medications, treatment

Posted By: Aspen Education Group